Haloperidol Krka

Haloperidol Krka is a prescription medication that contains the active ingredient haloperidol, a butyrophenone antipsychotic, supplied in an oral dosage form. It is marketed in the European Union and is classified under ATC code N05AD01. Haloperidol works primarily as a dopamine D2 receptor antagonist and is used under medical supervision for certain psychiatric conditions.

Haloperidol Krka is indicated for the management of several neuropsychiatric disorders where dopamine blockade is beneficial.

- Treatment of schizophrenia in adults and adolescents. - Control of acute psychotic episodes. - Management of Tourette syndrome symptoms. - Adjunct therapy for severe agitation or aggression. - Short‑term use in postoperative or intensive‑care settings when rapid sedation is required.

Side effects of haloperidol can vary in frequency and severity.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor or rigidity. - Dry mouth. - Constipation. - Blurred vision. - Weight gain.

Serious: - Neuroleptic malignant syndrome. - Tardive dyskinesia. - Severe hypotension. - Cardiac arrhythmias (QT prolongation). - Hyperprolactinemia leading to hormonal disturbances.

Before starting Haloperidol Krka, clinicians should evaluate patient history and monitor for potential risks.

- Assess cardiovascular status, especially QT interval. - Review history of movement disorders or Parkinsonian symptoms. - Use caution in patients with hepatic or renal impairment. - Monitor for signs of neuroleptic malignant syndrome. - Evaluate pregnancy or breastfeeding status, as safety data are limited. - Adjust dose in elderly patients to reduce fall risk.

Haloperidol may interact with several drug classes, influencing efficacy or safety.

Avoid: - Other dopamine antagonists or antipsychotics that increase extrapyramidal risk. - Medications that prolong QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Strong CYP3A4 inhibitors that raise haloperidol plasma levels.

Use with caution: - CNS depressants such as benzodiazepines or opioids. - Anticholinergic agents that may mask extrapyramidal signs. - Drugs affecting electrolyte balance, which can exacerbate cardiac effects. - Alcohol, due to additive sedation.